Cox regression of risk factors on TFS in lung cancer
| Parameter . | TFS . | |||
|---|---|---|---|---|
| UVA . | MVA . | |||
| VTE HR (95% CI) . | P value . | VTE HR (95% CI) . | P value . | |
| Age ≥60 y | 0.52 (0.32-0.86) | .011 | 0.53 (0.32-0.87) | .012 |
| Male sex | 0.93 (0.57-1.52) | .779 | NA | |
| Race | ||||
| White | Ref | NA | ||
| Black | 0.90 (0.36-2.24) | .818 | NA | |
| Other/unknown | 0.59 (0.08-4.37) | .607 | NA | |
| Ethnicity | ||||
| Non-Hispanic | Ref | NA | ||
| Hispanic | 1.50 (0.91-2.46) | .113 | NA | |
| Unknown | 2.03 (0.62-6.57) | .240 | NA | |
| Tobacco history | ||||
| None/never used | Ref | |||
| Any current/prior use | 0.94 (0.53-1.66) | .827 | ||
| Baseline WBC ≥11 × 109/L | 1.72 (1.04-2.87) | .036 | 1.65 (1.00-2.72) | .050 |
| Baseline Hb <10 g/dL | 0.71 (0.28-1.78) | .463 | NA | |
| Baseline Plt ≥350 × 109/L | 1.24 (0.74-2.08) | .423 | NA | |
| BMI, kg/m2 | ||||
| <18.5 | 0.81 (0.24-2.71) | .737 | ||
| 18.5-24.9 | Ref | |||
| ≥25-25.9 | 1.05 (0.63-1.75) | .849 | NA | |
| KS | ||||
| 1-2 | Ref | |||
| 3-4 | 1.89 (1.08-3.31) | .027 | 1.73 (0.99-3.03) | .054 |
| Lung cancer type | ||||
| AC | Ref | NA | ||
| SCC | 0.73 (0.36-1.48) | .385 | ||
| NSCLC, NOS | 1.37 (0.53-3.50) | .517 | ||
| SCLC | 0.57 (0.24-1.34) | .198 | ||
| Unknown/other | 1.35 (0.18-10.37) | .773 | ||
| AJCC stage | ||||
| I-II | Ref | Ref | ||
| III-IV | 2.09 (0.91-4.81) | .084 | 1.76 (0.51-6.14) | .373 |
| Unknown | NE | NE | ||
| Therapy type | ||||
| Chemotherapy | 0.90 (0.27-2.98) | .868 | NA | |
| Chemoimmunotherapy | 1.18 (0.37-3.78) | .776 | ||
| Targeted therapy | 0.94 (0.25-3.58) | .927 | ||
| Radiation therapy | 1.28 (0.79-2.08) | .324 | ||
| Surgery | 0.54 (0.27-1.05) | .067 | 0.90 (0.34-2.41) | .839 |
| Parameter . | TFS . | |||
|---|---|---|---|---|
| UVA . | MVA . | |||
| VTE HR (95% CI) . | P value . | VTE HR (95% CI) . | P value . | |
| Age ≥60 y | 0.52 (0.32-0.86) | .011 | 0.53 (0.32-0.87) | .012 |
| Male sex | 0.93 (0.57-1.52) | .779 | NA | |
| Race | ||||
| White | Ref | NA | ||
| Black | 0.90 (0.36-2.24) | .818 | NA | |
| Other/unknown | 0.59 (0.08-4.37) | .607 | NA | |
| Ethnicity | ||||
| Non-Hispanic | Ref | NA | ||
| Hispanic | 1.50 (0.91-2.46) | .113 | NA | |
| Unknown | 2.03 (0.62-6.57) | .240 | NA | |
| Tobacco history | ||||
| None/never used | Ref | |||
| Any current/prior use | 0.94 (0.53-1.66) | .827 | ||
| Baseline WBC ≥11 × 109/L | 1.72 (1.04-2.87) | .036 | 1.65 (1.00-2.72) | .050 |
| Baseline Hb <10 g/dL | 0.71 (0.28-1.78) | .463 | NA | |
| Baseline Plt ≥350 × 109/L | 1.24 (0.74-2.08) | .423 | NA | |
| BMI, kg/m2 | ||||
| <18.5 | 0.81 (0.24-2.71) | .737 | ||
| 18.5-24.9 | Ref | |||
| ≥25-25.9 | 1.05 (0.63-1.75) | .849 | NA | |
| KS | ||||
| 1-2 | Ref | |||
| 3-4 | 1.89 (1.08-3.31) | .027 | 1.73 (0.99-3.03) | .054 |
| Lung cancer type | ||||
| AC | Ref | NA | ||
| SCC | 0.73 (0.36-1.48) | .385 | ||
| NSCLC, NOS | 1.37 (0.53-3.50) | .517 | ||
| SCLC | 0.57 (0.24-1.34) | .198 | ||
| Unknown/other | 1.35 (0.18-10.37) | .773 | ||
| AJCC stage | ||||
| I-II | Ref | Ref | ||
| III-IV | 2.09 (0.91-4.81) | .084 | 1.76 (0.51-6.14) | .373 |
| Unknown | NE | NE | ||
| Therapy type | ||||
| Chemotherapy | 0.90 (0.27-2.98) | .868 | NA | |
| Chemoimmunotherapy | 1.18 (0.37-3.78) | .776 | ||
| Targeted therapy | 0.94 (0.25-3.58) | .927 | ||
| Radiation therapy | 1.28 (0.79-2.08) | .324 | ||
| Surgery | 0.54 (0.27-1.05) | .067 | 0.90 (0.34-2.41) | .839 |
A total of 632 patients were included in the analysis, and 64 events occurred.
MVA, multivariate analysis; NA, not applicable; NE, not estimable; Ref, reference population; UVA, univariate analysis.